Literature DB >> 19464855

The "Functional Remission of General Schizophrenia" (FROGS) scale: development and validation of a new questionnaire.

Pierre-Michel Llorca1, Christophe Lançon, Sylvie Lancrenon, Franck-Jean Bayle, Hervé Caci, Frédéric Rouillon, Philip Gorwood.   

Abstract

Functional remission is an important treatment goal in schizophrenia, as independent living and reintegration of patients into the community and the workplace is the ultimate goal of any treatment. Nevertheless, assessing functional remission in schizophrenia is problematic, as it is a multifactorial and complex entity reflecting various aspects such as symptoms severity, personal skills and socio-cultural expectancies. The purpose of this study was to create and validate a novel scale for the evaluation of functional remission in schizophrenia. Unlike previous scales, the scale was built on the basis of patients with few schizophrenia symptoms. The "Functional Remission of General Schizophrenia" (FROGS) scale was developed using the expert consensus method following a MEDLINE and standard database search. Out of the 61 initially proposed, 19 items were selected as gathering the core aspects of functional remission in schizophrenia detected in the literature. The FROGS was then evaluated in 432 patients with DSM-IV criteria of schizophrenia, all of them meeting the symptomatic remission criteria of Andreasen et al. [Andreasen, N.C., Carpenter, W.T., Kane, J.M., Lasser, R.A., Marder, S.R., Weinberger, D.R., 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162 441-449]. Total score was highly reliable. Exploratory factor analysis after oblique rotation revealed that a three-factor solution was the most meaningful. On the basis of item content these three factors were labelled 'Social Functioning,' 'Daily Life' and 'Treatment.' The FROGS total score can be used to measure a general construct for the evaluation of functional remission in schizophrenia.. Further work is required to measure the acceptability, predictive validity, sensitivity to change, and stability of the factor structure of the FROGS.

Entities:  

Mesh:

Year:  2009        PMID: 19464855     DOI: 10.1016/j.schres.2009.04.029

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  14 in total

Review 1.  Surgical Management of Obesity Among People with Schizophrenia and Bipolar Disorder: a Systematic Review of Outcomes and Recommendations for Future Research.

Authors:  Youssef Kouidrat; Ali Amad; Brendon Stubbs; Suzan Moore; Fiona Gaughran
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

2.  Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia.

Authors:  G Fond; M Faugere; C Faget-Agius; M Cermolacce; R Richieri; L Boyer; C Lançon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-08-04       Impact factor: 5.270

3.  The Effect of Mindfulness-Based Psychosocial Skills Training on Functioning and Insight Level in Patients with Schizophrenia.

Authors:  Arzu Yüksel; Emel Bahadır-Yılmaz
Journal:  Community Ment Health J       Date:  2020-06-13

4.  Construct Validity of the Chinese Version of the Activities of Daily Living Rating Scale III in Patients with Schizophrenia.

Authors:  En-Chi Chiu; Yen Lee; Kuan-Yu Lai; Chian-Jue Kuo; Shu-Chun Lee; Ching-Lin Hsieh
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

5.  The Youth Mental Health Risk and Resilience Study (YouR-Study).

Authors:  Peter J Uhlhaas; Ruchika Gajwani; Joachim Gross; Andrew I Gumley; Stephen M Lawrie; Matthias Schwannauer
Journal:  BMC Psychiatry       Date:  2017-01-26       Impact factor: 3.630

6.  Assessment of the efficacy of a fatigue management therapy in schizophrenia: study protocol for a randomized, controlled multi-centered study (ENERGY).

Authors:  Stéphane Raffard; Nicolas Rainteau; Sophie Bayard; Yasmine Laraki; Joanna Norton; Delphine Capdevielle
Journal:  Trials       Date:  2020-09-17       Impact factor: 2.279

7.  Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial.

Authors:  Andreas Meyer-Lindenberg; Peter Falkai; Isabel Maurus; Alkomiet Hasan; Andrea Schmitt; Astrid Roeh; Daniel Keeser; Berend Malchow; Thomas Schneider-Axmann; Martin Hellmich; Sabine Schmied; Moritz Lembeck; Katriona Keller-Varady; Irina Papazova; Dusan Hirjak; Cristina E Topor; Henrik Walter; Sebastian Mohnke; Bob O Vogel; Wolfgang Wölwer; Frank Schneider; Karsten Henkel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-08-03       Impact factor: 5.270

8.  Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa.

Authors:  Philip Gorwood; Tom Burns; Georg Juckel; Alessandro Rossi; Luis San; Ludger Hargarter; Andreas Schreiner
Journal:  Ann Gen Psychiatry       Date:  2013-03-26       Impact factor: 3.455

9.  Symptomatic remission affects employment outcomes in schizophrenia patients.

Authors:  San-Ping Wang; Jung-Der Wang; Jer-Hao Chang; Bo-Jian Wu; Tso-Jen Wang; Hsiao-Ju Sun
Journal:  BMC Psychiatry       Date:  2020-05-12       Impact factor: 3.630

10.  Idiographic analyses of motivation and related processes in participants with schizophrenia following a therapeutic intervention for negative symptoms.

Authors:  Bénédicte Thonon; Evelyne Van Aubel; Ginette Lafit; Clara Della Libera; Frank Larøi
Journal:  BMC Psychiatry       Date:  2020-09-25       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.